Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Text Size

Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders

This study has been completed.
Sponsor:
Information provided by:
Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov Identifier:
NCT00036127
First received: May 7, 2002
Last updated: November 7, 2013
Last verified: September 2007
History of Changes
  Purpose
Study to learn if the alternate formulation is effective in agitated schizophrenic patients

Condition Intervention Phase
Schizophrenia
 Drug: aripiprazole
 Phase 2
Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:

MedlinePlus related topics: Schizophrenia
U.S. FDA Resources

Further study details as provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:
Study Start Date: April 2002
Study Completion Date: January 2003
Primary Completion Date: January 2003 (Final data collection date for primary outcome measure)
  Eligibility
Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Agitated schizophrenic patients
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00036127

Locations
United States, California
Local Institution
Anaheim, California, United States
Local Institution
Cerritos, California, United States
Local Institution
Chula Vista, California, United States
Local Institution
Rosemead, California, United States
Local Institution
San Diego, California, United States
United States, Georgia
Local Institution
Atlanta, Georgia, United States
Local Institution
Macon, Georgia, United States
United States, Illinois
Local Instituton
Hoffman Estates, Illinois, United States
United States, Nevada
Local Institution
Las Vegas, Nevada, United States
United States, New Hampshire
Local Institution
Nashua, New Hampshire, United States
United States, New York
Local Institution
New York, New York, United States
United States, Ohio
Local Institution
Beachwood, Ohio, United States
United States, Pennsylvania
Local Institution
Philadelphia, Pennsylvania, United States
United States, South Carolina
Local Institution
Charleston, South Carolina, United States
United States, Texas
Local Institution
Houston, Texas, United States
United States, Wisconsin
Local Institution
Milwaukee, Wisconsin, United States
Sponsors and Collaborators
Otsuka Pharmaceutical Development & Commercialization, Inc.
  More Information

Additional Information:
BMS Clinical Trials Disclosure  This link exits the ClinicalTrials.gov site
For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm  This link exits the ClinicalTrials.gov site

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT00036127     History of Changes
Other Study ID Numbers: CN138-050
Study First Received: May 7, 2002
Last Updated: November 7, 2013

Keywords provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:
agitated schizophrenic patients

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Aripiprazole
Antipsychotic Agents
 Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs

ClinicalTrials.gov processed this record on May 24, 2017